A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol [SUBSTUDY OF 700216591]
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms ADAPT-HER2+HR-
Most Recent Events
- 26 Feb 2025 Status changed from active, no longer recruiting to completed.
- 13 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2024 Planned primary completion Date changed from 1 Aug 2015 to 1 Jan 2025.